On Wednesday, Moderna shares in Frankfurt rose by around 15 percent. The month-long sideways trend thus seems to have been broken. The US group sold more vaccines in the second quarter than the market expected.
Moderna is making a fortune with its Spikevax vaccine. The biotech company opened its books on the most recent quarter yesterday, Wednesday, and exceeded all expectations: The Americans were able to increase their sales by nine percent year-on-year to $4.7 billion despite the slowdown in vaccination rates worldwide. Bloomberg analysts, on the other hand, had expected a decline in sales.
The group only has to cope with a small damper in terms of net profit. The bottom line is that he was left with $ 2.2 billion less than in Q2 2021. Moderna cites increased costs for production, sales and personnel as well as write-offs on vaccines with an expired expiration date as the reasons for this.
However, a look at the first half of the year is even more impressive: By the end of June, Moderna had made a whopping 10.5 billion dollars with its mRNA vaccine – a big increase of 76 percent compared to the same period last year.
Also getting investors’ hearts racing was the announcement by Moderna CEO Stéphane Bancel that the board had approved a new $3 billion share buyback program thanks to the company’s strong financial position and business momentum.
The base prospectus as well as the final terms and the basic information sheets can be obtained by clicking on the disclaimer document. Please also note the further information on this advertisement.
